Journal ArticleDOI
Glioblastoma and Other Malignant Gliomas: A Clinical Review
Antonio Omuro,Lisa M. DeAngelis +1 more
TLDR
The clinical management of malignant gliomas is reviewed, including genetic and environmental risk factors such as cell phones, diagnostic pitfalls, symptom management, specific antitumor therapy, and common complications.Abstract:
Importance Glioblastomas and malignant gliomas are the most common primary malignant brain tumors, with an annual incidence of 5.26 per 100 000 population or 17 000 new diagnoses per year. These tumors are typically associated with a dismal prognosis and poor quality of life. Objective To review the clinical management of malignant gliomas, including genetic and environmental risk factors such as cell phones, diagnostic pitfalls, symptom management, specific antitumor therapy, and common complications. Evidence Review Search of PubMed references from January 2000 to May 2013 using the terms glioblastoma , glioma , malignant glioma , anaplastic astrocytoma , anaplastic oligodendroglioma , anaplastic oligoastrocytoma , and brain neoplasm . Articles were also identified through searches of the authors’ own files. Evidence was graded using the American Heart Association classification system. Findings Only radiation exposure and certain genetic syndromes are well-defined risk factors for malignant glioma. The treatment of newly diagnosed glioblastoma is based on radiotherapy combined with temozolomide. This approach doubles the 2-year survival rate to 27%, but overall prognosis remains poor. Bevacizumab is an emerging treatment alternative that deserves further study. Grade III tumors have been less well studied, and clinical trials to establish standards of care are ongoing. Patients with malignant gliomas experience frequent clinical complications, including thromboembolic events, seizures, fluctuations in neurologic symptoms, and adverse effects from corticosteroids and chemotherapies that require proper management and prophylaxis. Conclusions and Relevance Glioblastoma remains a difficult cancer to treat, although therapeutic options have been improving. Optimal management requires a multidisciplinary approach and knowledge of potential complications from both the disease and its treatment.read more
Citations
More filters
Journal ArticleDOI
Mutational landscape and clonal architecture in grade II and III gliomas
Hiromichi Suzuki,Kosuke Aoki,Kenichi Chiba,Yusuke Sato,Yusuke Shiozawa,Yuichi Shiraishi,Teppei Shimamura,Atsushi Niida,Kazuya Motomura,Fumiharu Ohka,Takashi Yamamoto,Kuniaki Tanahashi,Melissa Ranjit,Toshihiko Wakabayashi,Tetsuichi Yoshizato,Keisuke Kataoka,Kenichi Yoshida,Yasunobu Nagata,Aiko Sato-Otsubo,Hiroko Tanaka,Masashi Sanada,Yutaka Kondo,Hideo Nakamura,Masahiro Mizoguchi,Tatsuya Abe,Yoshihiro Muragaki,Reiko Watanabe,Ichiro Ito,Satoru Miyano,Atsushi Natsume,Seishi Ogawa +30 more
TL;DR: In this article, the authors delineate the entire picture of genetic alterations and affected pathways in these glioma types, with sensitive detection of driver genes Grade II and III gliomas comprise three distinct subtypes characterized by discrete sets of mutations and distinct clinical behaviors, suggesting that there is functional interplay between the mutations that drive clonal selection.
Journal ArticleDOI
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon,Alba A. Brandes,Antonio Omuro,Paul Mulholland,Michael Lim,Antje Wick,Joachim M. Baehring,Manmeet Ahluwalia,Patrick Roth,Oliver Bähr,Surasak Phuphanich,Juan Manuel Sepúlveda,Paul de Souza,Solmaz Sahebjam,Michael Carleton,Kay Tatsuoka,Corina Taitt,Ricardo Zwirtes,John Sampson,Michael Weller +19 more
TL;DR: Nivolumab monotherapy did not improve overall survival compared with bevacizumab in the treatment of recurrent glioblastoma, and additional research is needed to find out why.
Journal ArticleDOI
Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment
Farina Hanif,Farina Hanif,Kanza Muzaffar,Kahkashan Perveen,Saima Mehmood Malhi,Shabana Usman Simjee +5 more
TL;DR: It was found that radiation and certain genetic syndromes are the only risk factors identified to date for GBM, and the pathogenesis to involve aberrations of multiple signaling pathways through multiple genetic mutations and altered gene expression.
Journal ArticleDOI
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma
Leticia De Mattos-Arruda,Leticia De Mattos-Arruda,Leticia De Mattos-Arruda,Regina Mayor,Charlotte K.Y. Ng,Britta Weigelt,Francisco Martínez-Ricarte,Francisco Martínez-Ricarte,Davis Y. Torrejon,Mafalda Oliveira,Alexandra Arias,C. Raventós,Jiabin Tang,Elena Guerini-Rocco,Elena Martínez-Sáez,Sergio Lois,Oscar Marín,Xavier de la Cruz,Xavier de la Cruz,Salvatore Piscuoglio,Russel Towers,Ana Vivancos,Vicente Peg,Santiago Ramón y Cajal,Santiago Ramón y Cajal,Joan Carles,Jordi Rodon,Maria Gonzalez-Cao,Josep Tabernero,Josep Tabernero,Enriqueta Felip,Enriqueta Felip,Joan Sahuquillo,Joan Sahuquillo,Michael F. Berger,Javier Cortes,Javier Cortes,Jorge S. Reis-Filho,Joan Seoane,Joan Seoane,Joan Seoane +40 more
TL;DR: It is shown that ctDNA derived from central nervous system tumours is more abundantly present in the cerebrospinal fluid (CSF) than in plasma, allowing the identification of actionable brain tumour somatic mutations and facilitating and complement the diagnosis of leptomeningeal carcinomatosis.
Journal ArticleDOI
Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances.
Richard A. Revia,Miqin Zhang +1 more
TL;DR: Recent applications of magnetite NPs in diagnosis, treatment, and treatment monitoring of cancer are addressed and some views will be discussed concerning the toxicity and clinical translation of iron oxide NPs.
References
More filters
Journal ArticleDOI
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
TL;DR: The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity.
Journal ArticleDOI
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.
Quinn T. Ostrom,Haley Gittleman,Peter Liao,Chaturia Rouse,Yanwen Chen,Jacqueline Dowling,Yingli Wolinsky,Carol Kruchko,Jill S. Barnholtz-Sloan +8 more
TL;DR: The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the US.
Journal ArticleDOI
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Monika E. Hegi,Annie-Claire Diserens,Thierry Gorlia,Marie-France Hamou,Nicolas de Tribolet,Nicolas de Tribolet,Michael Weller,Johan M. Kros,Johannes A. Hainfellner,Warren P. Mason,Luigi Mariani,Jacoline E C Bromberg,Peter Hau,René O. Mirimanoff,J. Gregory Cairncross,Robert C. Janzer,Roger Stupp +16 more
TL;DR: Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylation of theMGMT promoter did notHave such a benefit and were assigned to only radiotherapy.
Journal ArticleDOI
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G.W. Verhaak,Katherine A. Hoadley,Elizabeth Purdom,Victoria Wang,Yuan-yuan Qi,Matthew D. Wilkerson,C. Ryan Miller,Li Ding,Todd R. Golub,Jill P. Mesirov,Gabriele Alexe,Michael S. Lawrence,Michael O'Kelly,Pablo Tamayo,Barbara A. Weir,Stacey Gabriel,Wendy Winckler,Supriya Gupta,Lakshmi Jakkula,Heidi S. Feiler,J. Graeme Hodgson,C. David James,Jann N. Sarkaria,Cameron Brennan,Ari B. Kahn,Paul T. Spellman,Richard K. Wilson,Terence P. Speed,Terence P. Speed,Joe W. Gray,Matthew Meyerson,Gad Getz,Charles M. Perou,Charles M. Perou,D. Neil Hayes +34 more
TL;DR: A robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes is described and multidimensional genomic data is integrated to establish patterns of somatic mutations and DNA copy number.
Book
WHO classification of tumours of the central nervous system
TL;DR: The current edition of the WHO Classification of Tumours of the Central Nervous System will serve as an indispensable textbook for all of those involved in the diagnosis and management of patients with tumors of the CNS, and will make a valuable addition to libraries in pathology, radiology, oncology, and neurosurgery departments.
Related Papers (5)
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G.W. Verhaak,Katherine A. Hoadley,Elizabeth Purdom,Victoria Wang,Yuan-yuan Qi,Matthew D. Wilkerson,C. Ryan Miller,Li Ding,Todd R. Golub,Jill P. Mesirov,Gabriele Alexe,Michael S. Lawrence,Michael O'Kelly,Pablo Tamayo,Barbara A. Weir,Stacey Gabriel,Wendy Winckler,Supriya Gupta,Lakshmi Jakkula,Heidi S. Feiler,J. Graeme Hodgson,C. David James,Jann N. Sarkaria,Cameron Brennan,Ari B. Kahn,Paul T. Spellman,Richard K. Wilson,Terence P. Speed,Terence P. Speed,Joe W. Gray,Matthew Meyerson,Gad Getz,Charles M. Perou,Charles M. Perou,D. Neil Hayes +34 more